ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 233

New Cardiovascular Risk Factors Screening in Patients with Gout

Juan Carlos Ordoñez1, Mariano Andres1, Francisca Sivera2, Loreto Carmona3, Paloma Vela4,5, Eliseo Pascual4,5 and Jose Antonio Bernal4, 1RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, 2RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ELDA, Elda, Spain, 3Instituto de Salud Musculo Esqueletica, Madrid, Spain, 4RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO ALICANTE, Alicante, Spain, 5Medicina, Universidad Miguel Hernandez, Elche, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cardiovascular disease, Co-morbidities, Gout and uric acid

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is a disease triggered by the crystallization of uric acid in the joints secondary to persistent hyperuricemia, that leads to chronic inflammation. Patients with gout frequently have comorbidities including cardiovascular (CV) disease, kidney failure, diabetes mellitus etc. In fact, some these can increase the levels of uric acid and contribute to develop gout, and also deteriorate the CV profile of these patients. The aim of the present study was to assess the prevalence of unknown cardiovascular risk factors (CVRF) in patients with gout.  

Methods : Cross-sectional analysis of a inception cohort of gout patients recruited by consecutive sampling in our rheumatology unit. Gout was diagnosed by visualization of monosodium urate crystals in synovial fluid or tophus sample. A structured CV assessment included CVRF, measurement of blood pressure, anthropometry and lab tests. Arterial Hypertension (AH) was defined by previous diagnosis, blood pressure ≥140/90mmHg and/or use of antihypertensive agents. Type 2 Diabetes Mellitus (DM-2) was defined by previous diagnosis, fasting blood glucose ≥126 mg/dL, glycosylated haemoglobin ≥6.5%; presence of microangiopathic complications was also registered. Dyslipidemia (DLP) was defined by previous diagnosis, use of hypolipidemic agents, or total cholesterol >200 mg/dL and/or triglycerides > 150 mg/dL. A descriptive analysis of the results is presented.

Results : The study involved 199 patients. The mean age was 63.4 (SD+/- 13.2) years, with 171 (85.9%) men. At inclusion the prevalence of CVRF was: AH in 136 patients (68.3%), DLP in 13 (51.8%), and DM-2 in 47 (23.6%). Seventy-six (38.6%) were found obese, smoking background was present in 40 (20.1%), use of diuretics (loop and/or thiazide) in 87 (43.7%), and chronic renal failure in 57 (28.6%). After structured assessment, the following undiagnosed CVRF were found: DLP in 59 patients (29.6%), AH in 20 (10.1%) and DM-2 in 14 (7%) [Figure]. New CVRF were found in 94 (46.7%) patients, among them 52 (26.1 %) had one CVRF, 13 (6.5%) had 2 CVRF, and even 3 CVRF were identified in 2 cases (1.0%).

Conclusion : Half of our patients showed at least one unknown CVRF, mostly DLP followed by hypertension and DM-2. This finding highlights the need for active screening for new CVRF in patients diagnosed with gout, due to the potential impact on the proper CV management.


Disclosure: J. C. Ordoñez, None; M. Andres, None; F. Sivera, None; L. Carmona, None; P. Vela, None; E. Pascual, None; J. A. Bernal, None.

To cite this abstract in AMA style:

Ordoñez JC, Andres M, Sivera F, Carmona L, Vela P, Pascual E, Bernal JA. New Cardiovascular Risk Factors Screening in Patients with Gout [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/new-cardiovascular-risk-factors-screening-in-patients-with-gout/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-cardiovascular-risk-factors-screening-in-patients-with-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology